Abbott/Genelabs
This article was originally published in The Gray Sheet
Executive Summary
Enter agreement granting Abbott a worldwide, non-exclusive license to develop and commercialize diagnostic and screening products for "hepatitis X virus." Genelabs says the virus, which has not been characterized, "is believed to be an agent responsible for transfusion-transmitted hepatitis not caused by hepatitis B or C viruses." Under the agreement, Genelabs will receive from Abbott license and milestone payments that could exceed $10 mil., as well as royalties on sales by Abbott of HXV products. Genelabs retains the right to develop HXV confirmatory tests. The agreement builds on a similar deal between the two companies covering hepatitis E virus diagnostics products. Genelabs launched an HEV screening test in Asia in June ("The Gray Sheet" June 8, I&W-2)....
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.